Executive record

Amy Burroughs, M.B.A.

Director at Tenaya Therapeutics, Inc.

Follow
More
Challenge a Claim

Alpha ID: alpha:person:amy-burroughs-m-b-aVersion: public-0As of: 2026-09-28

Not yet claimed9 published Claims3 sources
  • Director

Key Claims

Biography

Amy Burroughs has served as CEO of Terns Pharmaceuticals since February 2024, a publicly traded clinical-stage biopharmaceutical company. Previously, she was President and CEO of Cleave Therapeutics and held executive roles in commercial and strategy at Genentech and other biotechnology companies. She holds a BA in Computer Science from Dartmouth College and an MBA from Harvard Business School.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Board service

Boards

Claims

Executive career

  1. Dates not publishedExecutive title: Chief Executive Officer and Board member · Organization not publishedTNYA DEF 14A director slate

Claims

Conflicts and accountability

Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

3 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. TNYA DEF 14A director slate

    sec filing · Source published: Apr 16, 2026 · Retrieved: May 16, 2026

    Supports 7 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Board role: Board role: Director · Claim reviewed: May 16, 2026
    • Committee assignments: Committee assignments: Audit, Compensation · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Executive company: Executive at Terns Pharmaceuticals, Inc. · Claim reviewed: May 16, 2026
    • Executive title: Executive title: Chief Executive Officer and Board member · Claim reviewed: May 16, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  2. Open source

    sec proxy · Source published: Apr 16, 2026 · Retrieved: Apr 25, 2026

    Supports 1 claim
    • Professional Role: Director at Tenaya Therapeutics, Inc. · Claim reviewed: May 16, 2026

  3. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Tenaya Therapeutics, Inc. · Claim reviewed: May 16, 2026